S

Sanofi

Global pharma company; vaccines and R&D

Talent Acquisition Partner

Full-TimeUpdated on 10/23/2026Deadline 11/23/26
HUF9.1M - HUF13.7M
Mid
Budapest, Hungary
HybridHybrid work in Budapest.
People & HRGeneralist Recruiting

About the job

Requirements
  • Proven track record of recruiting strong talent.
  • Experience working with a global Centre of Excellence and driving standardization across multiple locations.
  • Strong candidate and stakeholder management skills.
  • Deep understanding of recruitment best practices, processes, and technologies, including Applicant Tracking Systems and human resources information systems.
  • Fluency in English and French.
  • Experience leading and managing global recruitment teams, operating within a global business services environment, and building new capability in talent teams.
Responsibilities
  • Manage the full recruitment process for open positions within the defined scope, including sourcing, screening, assessing, and selecting candidates.
  • Share talent and market intelligence reports with stakeholders and develop effective hiring strategies accordingly.
  • Own and lead the Talent Acquisition agenda for assigned positions and continuously improve quality of hires, time to hire, hiring-manager experience, and candidate experience.
  • Work with local business Human Resources and Talent Acquisition partners, stakeholders, talent management, communications, and procurement to ensure alignment, continuous improvement, and understanding of recruitment operations.
  • Participate in the global Talent Acquisition network and manage the team.
  • Monitor Talent Acquisition service-delivery service-level agreements and key performance indicators, and return on investment for technology and attraction strategies.
  • Build trusted advisor relationships with functional heads and key collaborators to keep talent acquisition central to strategic planning.
  • Use diverse sourcing channels to manage end-to-end recruitment processes and attract qualified candidates.
  • Support development of an employee value proposition relevant to the hub, collaborating with Lead Talent Acquisition and the hub employer-branding team.
  • Work with the Country Talent Management team to maintain a holistic view of available internal and external talent.
  • Use a data-driven approach and demonstrate return on investment through metrics.
  • Drive a strong talent assessment process to ensure delivery of the best talent.
  • Work with People and Organization, hiring managers, and colleagues to improve the hiring-manager and candidate experience.
  • Maintain data compliance across Talent Acquisition systems and tools, including Workday, job boards, and social media.
  • Provide periodic hiring-status reports to business stakeholders.
  • Share best practices, talent intelligence, and market insights to improve recruitment outcomes across hubs.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...